12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Abraxane nab-paclitaxel: Phase III data

Top-line data from the open-label, international Phase III CA033 trial in 529 chemotherapy-naïve patients with metastatic melanoma showed that 150 mg/m 2 Abraxane given on days 1, 8 and 15 every 4 weeks met the primary endpoint of PFS vs. dacarbazine. Celgene said the safety profile of...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >